Figure 2 | npj Primary Care Respiratory Medicine

Figure 2

From: Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease

Figure 2

Comparison of reduction in the rate of moderate/severe exacerbations with BDP/FF versus formoterol in COPD patients. Adapted from FORWARD study: all patients (Wedzicha et al.28) and data pooling from post hoc analysis on baseline blood eosinophil count (Siddiqui et al.35). BDP/FF, beclometasone dipropionate/formoterol. 20% is the suggested minimal clinically important difference for exacerbations.47

Back to article page